JYNT / The Joint Corp. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

The Joint Corp.
US ˙ NasdaqCM ˙ US47973J1025

Statistik Asas
CIK 1612630
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to The Joint Corp.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
August 27, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 The Joint Corp. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of

August 27, 2025 EX-10.1

SEPARATION AGREEMENT AND RELEASE

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release of Claims (this “Release”) is entered into by and between The Joint Corp., a Delaware corporation with a principal business address at 16767 N. Perimeter Drive, Suite 110, Scottsdale, AZ 85260 (the “Company”), and Jake Singleton, an individual residing at [***] (“Executive”) to be effective as of the date set forth

August 12, 2025 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:

August 12, 2025 EX-97

The Joint Corp. Executive Officer Clawback Policy

The Joint Corp. Executive Officer Clawback Policy Effective as of December 1, 2023 (the “Adoption Date”) I.Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of The Joint Corp. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awarded Compensation to the Company. This Policy and any ter

August 12, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

August 12, 2025 EX-10.2

Asset Purchase Agreement, dated June 23, 2025, by and between the Registrant and Joint Ventures, LLC, a Nevada limited liability company

ASSET PURCHASE AGREEMENT between and among Joint Ventures, LLC, a Nevada limited liability company And The Joint Corp.

August 12, 2025 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36724 The J

August 12, 2025 NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36724 CUSIP Number: 47973J102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Trans

August 7, 2025 EX-99.1

The Joint Corp. Reports Second Quarter 2025 Financial Results - Refranchised 37 clinics; Franchises now represent 92% of the portfolio - - Acquired rights to the Northwest regional developer territory -

Exhibit 99.1 The Joint Corp. Reports Second Quarter 2025 Financial Results - Refranchised 37 clinics; Franchises now represent 92% of the portfolio - - Acquired rights to the Northwest regional developer territory - SCOTTSDALE, Ariz., August 7, 2025 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, posted operating highlights and limited financ

August 7, 2025 EX-99.2

NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Q2 2025 Financial Results As of June 30, 2025, reported August 7, 2025 1 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this

a25-08x07jyntq22025final NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Q2 2025 Financial Results As of June 30, 2025, reported August 7, 2025 1 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements." We have tried to identify these forward-looking statements by using words suc

August 7, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 The Joint Corp. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of

July 30, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 The Joint Corp. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of i

July 30, 2025 EX-99.1

The Joint Corp. Expects to Restate Full Year 2024 and First Quarter 2025 Financial Statements due to Overestimated Noncash Impairment Charges - Expects to reduce 2024 net loss and increase carrying value of assets held for sale by approximately $2.2

Exhibit 99.1 The Joint Corp. Expects to Restate Full Year 2024 and First Quarter 2025 Financial Statements due to Overestimated Noncash Impairment Charges - Expects to reduce 2024 net loss and increase carrying value of assets held for sale by approximately $2.2 million - - Expects to increase first quarter 2025 net income by approximately $0.5 million, resulting in a cumulative increase in carryi

July 7, 2025 EX-99.1

The Joint Corp. Closes Sale of 31 Corporate Clinics in Arizona and New Mexico and Acquires Regional Developer Rights in the Northwest Region - Proven Operator Grows to 96 Clinics and Commits to Open 10 Additional Clinics - - Sale Price Included $8.3

Exhibit 99.1 The Joint Corp. Closes Sale of 31 Corporate Clinics in Arizona and New Mexico and Acquires Regional Developer Rights in the Northwest Region - Proven Operator Grows to 96 Clinics and Commits to Open 10 Additional Clinics - - Sale Price Included $8.3 Million Plus Regional Developer Rights that Generated $855,000 in Royalties and Franchise Fees over the 12 Months Ended March 31, 2025 -

July 7, 2025 EX-99.2

The Joint Corp. Unaudited Pro Forma Condensed Consolidated Financial Information

Exhibit 99.2 The Joint Corp. Unaudited Pro Forma Condensed Consolidated Financial Information On June 23, 2025, we entered into an Asset Purchase Agreement with Joint Ventures, LLC, a Nevada limited liability company and our largest franchisee (“Joint Ventures”), pursuant to which we agreed to sell to Joint Ventures the assets of, and grant franchise rights to, 31 company-owned and managed clinics

July 7, 2025 8-K

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of i

June 27, 2025 EX-99.1

The Joint Corp. Signs Binding Agreement to Sell 31 Corporate Clinics in Arizona and New Mexico and to Acquire Regional Developer Rights in the Northwest Region and Refranchises Five Corporate Clinics in the Kansas City Region, Tracking to Become Larg

Exhibit 99.1 The Joint Corp. Signs Binding Agreement to Sell 31 Corporate Clinics in Arizona and New Mexico and to Acquire Regional Developer Rights in the Northwest Region and Refranchises Five Corporate Clinics in the Kansas City Region, Tracking to Become Largest Pure Play Chiropractic Care Franchise System - The Joint to Deploy Capital and Enhance Profitability Profile by Reducing Regional Dev

June 27, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 The Joint Corp. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of i

June 10, 2025 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of in

June 10, 2025 EX-99.1

The Joint Corp. Names Business Transformation and Growth Expert Scott J. Bowman Chief Financial Officer - Public and private company CFO with 30 years’ experience in restaurants, retail and CPG –

The Joint Corp. Names Business Transformation and Growth Expert Scott J. Bowman Chief Financial Officer - Public and private company CFO with 30 years’ experience in restaurants, retail and CPG – SCOTTSDALE, Ariz., June 10, 2025 – The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced Scott J. Bowman joined as Chief Fin

June 10, 2025 EX-10.1

Employment Agreement, dated June 10, 2025, by and between the Registrant and Scott J. Bowman

ACTIVE 702119151v3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into by and between The Joint Corporation, a Delaware corporation (the “Company”) and Scott Bowman (“Executive”) as of June 10, 2025 to be effective as of the Effective Date (as defined herein).

June 5, 2025 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of in

June 5, 2025 EX-99.2

1 The Joint Corp. Announces $5 Million Stock Repurchase Program SCOTTSDALE, Ariz., June 5, 2025 – The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced that its board of

1 The Joint Corp. Announces $5 Million Stock Repurchase Program SCOTTSDALE, Ariz., June 5, 2025 – The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced that its board of directors has authorized a stock repurchase program expected to begin in August 2025 under which the company may repurchase up to $5 million of its ou

June 5, 2025 EX-99.1

1 The Joint Corp. Appoints Sandi Karrmann as Director - Accomplished Global HR Executive with Deep Franchise and Healthcare Expertise, including CHRO Roles at Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International, to Join Board - SCOTT

a99125-06x04jyntbodkarrm 1 The Joint Corp. Appoints Sandi Karrmann as Director - Accomplished Global HR Executive with Deep Franchise and Healthcare Expertise, including CHRO Roles at Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International, to Join Board - SCOTTSDALE, Ariz., June 4, 2025 – The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The J

May 22, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 21, 2025 The Joint Corp. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 21, 2025 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file numbe

May 9, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

May 8, 2025 EX-99.1

The Joint Corp. Reports First Quarter 2025 Financial Results - Grew revenue from continuing operations 7% compared to Q1 2024 - - Increased system-wide sales 5% for Q1 2025, demonstrating economic resilience -

99.1 The Joint Corp. Reports First Quarter 2025 Financial Results - Grew revenue from continuing operations 7% compared to Q1 2024 - - Increased system-wide sales 5% for Q1 2025, demonstrating economic resilience - SCOTTSDALE, Ariz., May 8, 2025 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter end

May 8, 2025 EX-99.2

NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Q1 2025 Financial Results As of March 31, 2025, reported May 8, 2025 1 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this p

NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Q1 2025 Financial Results As of March 31, 2025, reported May 8, 2025 1 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements." We have tried to identify these forward-looking statements by using words such as "may," "might," " will

May 8, 2025 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of inc

April 8, 2025 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Fee paid previously with preliminary materials.Confidential, for Use of the Commission Only (as permitte

April 8, 2025 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Fee paid previously with preliminary materials.Confidential, for Use of the Commission Only (as permitte

March 14, 2025 EX-19.1

Insider trading policies and procedures

Exhibit 19.1 Insider Trading Policy Introduction This Insider Trading Policy (the “Policy”) provides guidelines to employees, officers and directors of The Joint Corp. (the “Company” or “The Joint”) with respect to transactions in the Company’s securities. The Company has adopted this policy and the procedures set forth herein to help prevent insider trading and to assist the Company’s employees,

March 14, 2025 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36724 The Joint Corp. (Exact na

March 14, 2025 EX-10.51

Executive Short-Term Incentive Plan (STIP) (Amended March 10, 2025)

Exhibit 10.51 The Joint Corp. Executive Short-Term Incentive Plan (STIP) (Amended and Restated March 10, 2025) Plan Summary The Joint Corp. (“the Company”) Executive Short-Term Incentive Plan (“Executive STIP”) is an annual bonus plan. The Executive STIP Pool earned for each year will be determined based on achievement against metrics (the “STIP Metrics”) established by the Compensation Committee

March 14, 2025 EX-10.43

Form of Restricted Stock Award (The Joint Corp. 2024 Incentive Stock Plan)

Exhibit 10.43 [[FIRSTNAME]] [[MIDDLENAME]] [[LASTNAME]] Restricted Stock Award (The Joint Corp. 2024 Incentive Stock Plan) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as of the following grant date (the Grant Date), the following number of restricted shares (the Restricted Shares), which will beco

March 14, 2025 EX-10.42

Form of Stock Option Agreement (Nonstatutory Stock Option Granted Under The Joint Corp. 2024 Incentive Stock Plan)

Exhibit 10.42 [[FIRSTNAME]] [[MIDDLENAME]] [[LASTNAME]] NSO Stock Option Agreement (Nonstatutory Stock Option Granted Under The Joint Corp. 2024 Incentive Stock Plan) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as of the following grant date (the Grant Date), an nonstatutory stock option (the Opti

March 14, 2025 EX-10.44

Executive Short-Term Incentive Plan (STIP) (Amended March 10, 2025)

Exhibit 10.44 Confidentiality and Nonsolicitation Agreement This Confidentiality and Nonsolicitation Agreement (this Agreement) is entered into by The Joint Corp., a Delaware corporation and [name of employee], an employee of the Company (Employee), as of , 20. Background: The Company has granted to Employee an award (the Award) under The Joint Corp. 2024 Incentive Stock Plan (the Plan). As a cond

March 14, 2025 EX-10.41

Form of Stock Option Agreement (Incentive Stock Option Granted Under The Joint Corp. 2024 Incentive Stock Plan)

Exhibit 10.41 [[FIRSTNAME]] [[MIDDLENAME]] [[LASTNAME]] ISO Stock Option Agreement (Incentive Stock Option Granted Under The Joint Corp. 2024 Incentive Stock Plan) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as of the following grant date (the Grant Date), an incentive stock option (the Option) to

March 13, 2025 EX-99.1

The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results - Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 - - Increased system-wide sales 9% for both the year and Q4 2024 –

99.1 The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results - Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 - - Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, report

March 13, 2025 EX-99.2

NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Q4 2024 Financial Results As of December 31, 2024, reported March 13, 2025 1 Exhibit 99.2 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements

NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Q4 2024 Financial Results As of December 31, 2024, reported March 13, 2025 1 Exhibit 99.2 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements." We have tried to identify these forward-looking statements by using words such as "ma

March 13, 2025 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of

January 16, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File N

January 16, 2025 EX-99.1

The Joint Corp. Reports 2024 Operating Metrics - Adjustments Performed in 2024 Grows 9%, Compared to 2023 - - Receives Letters of Intent for the majority of the Corporate Portfolio in Early January 2025 -

EXHIBIT 99.1 The Joint Corp. Reports 2024 Operating Metrics - Adjustments Performed in 2024 Grows 9%, Compared to 2023 - - Receives Letters of Intent for the majority of the Corporate Portfolio in Early January 2025 - SCOTTSDALE, Ariz., Jan. 16, 2025 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, provided operating metrics f

December 23, 2024 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission File Numb

December 23, 2024 EX-10.1

Amended and Restated Nomination and Standstill Agreement, dated as of December 19, 2024, by and amount The Joint Corp., Bandera Master Fund L.P., Bandera Partners LLC, Gregory Bylinsky, and Jefferson Gramm

Exhibit 10.1        Section 1. AMENDED AND RESTATED NOMINATION AND STANDSTILL AGREEMENT This Amended and Restated Nomination and Standstill Agreement (as the same may be amended, this “Agreement”), dated as of December 19, 2024 (the “Effective Date”), is by and among The Joint Corp., a Delaware corporation (the “Company”), and the Persons (as defined below) set forth on the signature pages hereto

November 8, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The J

November 7, 2024 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer o

November 7, 2024 EX-99.2

Q3 2024 Results As of Sept. 30, 2024 | Reported on Nov. 7, 2024 99.2 Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements” about future events and expectations. Forward-looking statements are based

Q3 2024 Results As of Sept. 30, 2024 | Reported on Nov. 7, 2024 99.2 Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements” about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into acco

November 7, 2024 EX-99.1

The Joint Corp. Reports Third Quarter 2024 Financial Results

99.1 The Joint Corp. Reports Third Quarter 2024 Financial Results SCOTTSDALE, Ariz., November 7, 2024 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended September 30, 2024. Financial Highlights: Q3 2024 Compared to Q3 2023 ●Grew revenue 2% to $30.2 million. ●Reported net loss of $3.2 million,

October 15, 2024 EX-10.4

Stock Option Agreement, dated as of October 14, 2024, by and between the Registrant and Sanjiv Razdan

Exhibit 10.4 Sanjiv Razdan NSO Stock Option Agreement (Nonstatutory Stock Option Inducement Award) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as a material inducement to, and in connection with, Grantee’s acceptance of an offer of employment with the Company, as of the following grant date (the G

October 15, 2024 EX-10.5

Confidentiality and Nonsolicitation Agreement, dated as of October 14, 2024, by and between the Registrant and Sanjiv Razdan

Exhibit 10.5 Confidentiality and Nonsolicitation Agreement This Confidentiality and Nonsolicitation Agreement (this Agreement) is entered into by The Joint Corp., a Delaware corporation and Sanjiv Razdan , an employee of the Company (Employee), as of October 14, 2024. Background: The Company has granted to Employee an award (the Award) granted outside the terms of The Joint Corp. 2024 Incentive St

October 15, 2024 EX-10.1

Separation Agreement and Release, dated October 13, 2024, by and between the Registrant and Peter D. Holt

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release of Claims (this “Release”) is entered into by and between The Joint Corporation (the “Company”), and Peter D. Holt (“Executive”) to be effective as of the date set forth next to Executive’s signature below (the “Effective Date”). Executive and the Company are occasionally referred to herein as a “Party” or the “Par

October 15, 2024 EX-99.1

The Joint Corp. Appoints Sanjiv Razdan President and Chief Executive Officer -Seasoned Franchise Executive to also Join the Company’s Board of Directors-

EXHIBIT 99.1 The Joint Corp. Appoints Sanjiv Razdan President and Chief Executive Officer -Seasoned Franchise Executive to also Join the Company’s Board of Directors- SCOTTSDALE, Ariz., Oct. 14, 2024 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT) (“The Joint or “the Company”), the nation’s largest franchisor of chiropractic care through The Joint Chiropractic® network, welcomes Sanjiv Razdan as

October 15, 2024 EX-99.2

The Joint Corp. Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

EXHIBIT 99.2 The Joint Corp. Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SCOTTSDALE, Ariz., Oct. 15, 2024 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT) (“The Joint or “the Company”), the nation’s largest franchisor of chiropractic care through The Joint Chiropractic® network, today announced that it granted equity awards on October 14, 2024 as a material inducement to the

October 15, 2024 EX-10.2

Employment Agreement, dated October 14, 2024, by and between the Registrant and Sanjiv Razdan

Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into by and between The Joint Corporation, a Delaware corporation (the “Company”) and Sanjiv Razdan (“Executive”) as of October 14, 2024 to be effective as of the Effective Date (as defined herein). In this Agreement, the Company and Executive are occasionally referred to herein as a “party” or “the parties.”

October 15, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 The Joint Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File N

October 15, 2024 EX-10.3

Restricted Stock Award Grant Agreement, dated as of October 14, 2024, by and between the Registrant and Sanjiv Razdan

Exhibit 10.3 Sanjiv Razdan Restricted Stock Award (Inducement Award) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as a material inducement to, and in connection with, Grantee’s acceptance of an offer of employment with the Company, as of the following grant date (the Grant Date), the following numb

August 9, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

August 8, 2024 EX-99.2

Q2 2024 Financial Results As of June 30, 2024 | Reported on August 8, 2024 99.2 Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements” about future events and expectations. Forward-looking statements

Q2 2024 Financial Results As of June 30, 2024 | Reported on August 8, 2024 99.2 Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements” about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, takin

August 8, 2024 EX-99.1

The Joint Corp. Reports Second Quarter 2024 Financial Results - Grew Q2 2024 Revenue 3%, System-wide Sales 8% and System-wide Comp Sales 2% vs. Q2 2023 - - Increased Clinic Count to 960 at June 30, 2024 -

99.1 The Joint Corp. Reports Second Quarter 2024 Financial Results - Grew Q2 2024 Revenue 3%, System-wide Sales 8% and System-wide Comp Sales 2% vs. Q2 2023 - - Increased Clinic Count to 960 at June 30, 2024 - SCOTTSDALE, Ariz., August 8, 2024 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended

August 8, 2024 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of

May 29, 2024 EX-10.1

The Joint Corp. 2024 Incentive Stock Plan

Exhibit 10.1 The Joint Corp. 2024 Incentive Stock Plan Article 1 Purpose The purpose of this plan is to recognize and reward participants for their efforts on the Company’s behalf, to motivate participants by appropriate incentives to contribute to the Company’s attainment of its performance objectives, and to align participants’ interests with those of the Company’s other stockholders through com

May 29, 2024 S-8

As filed with the Securities and Exchange Commission on May 29, 2024

As filed with the Securities and Exchange Commission on May 29, 2024 Registration No.

May 29, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) The Joint Corp. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0

May 24, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 22, 2024 The Joint Corp. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 22, 2024 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission file number) (IRS employer o

May 24, 2024 EX-10.1

The Joint Corp. 2024 Incentive Stock Plan

Exhibit 10.1 The Joint Corp. 2024 Incentive Stock Plan Article 1 Purpose The purpose of this plan is to recognize and reward participants for their efforts on the Company’s behalf, to motivate participants by appropriate incentives to contribute to the Company’s attainment of its performance objectives, and to align participants’ interests with those of the Company’s other stockholders through com

May 13, 2024 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

May 3, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

May 2, 2024 EX-99.1

The Joint Corp. Reports First Quarter 2024 Financial Results - Grew Q1 2024 Revenue 5%, System-wide Sales 9%, and System-wide Comp Sales 3% vs. Q1 2023 - - Opened 23 Franchised Clinics, Increasing Clinic Count to 954 at March 31, 2024 - - Sold 15 Fra

EXHIBIT 99.1 The Joint Corp. Reports First Quarter 2024 Financial Results - Grew Q1 2024 Revenue 5%, System-wide Sales 9%, and System-wide Comp Sales 3% vs. Q1 2023 - - Opened 23 Franchised Clinics, Increasing Clinic Count to 954 at March 31, 2024 - - Sold 15 Franchise Licenses, Tripling Sales Compared to Q4 2023 - SCOTTSDALE, Ariz., May 2, 2024 – The Joint Corp. (NASDAQ: JYNT), a national operato

May 2, 2024 EX-99.2

Q1 2024 Financial Results As of March 31, 2024 | Reported on May 2, 2024 EXHIBIT 99.2 Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements” about future events and expectations. Forward-looking stat

Q1 2024 Financial Results As of March 31, 2024 | Reported on May 2, 2024 EXHIBIT 99.

May 2, 2024 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer of inc

April 19, 2024 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

March 8, 2024 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36724 The Joint Corp. (Exact na

March 7, 2024 EX-99.2

Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expectations of industry trends,

EXHIBIT 99.2 Q4 2023 Financial Results As of December 31, 2023 | Reported on March 7, 2024 Exhibit 99.2 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance

March 7, 2024 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Numb

March 7, 2024 EX-99.1

The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program -

EXHIBIT 99.1 The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March 07, 2024 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiro

February 13, 2024 SC 13G/A

JYNT / The Joint Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01258-jointcorpthe.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Joint Corp/The Title of Class of Securities: Common Stock CUSIP Number: 47973J102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the ru

January 12, 2024 SC 13G/A

JYNT / The Joint Corp. / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G/A 1 JYNTSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) THE JOINT CORP. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 47973J102 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate bo

November 13, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The J

November 9, 2023 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission File Numbe

November 9, 2023 EX-99.2

© 2023 The Joint Corp. All Rights Reserved. 3 Building upon Foundation for Growth 1 System - wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues

EXHIBIT 99.2 Q3 2023 Financial Results As of September 30, 2023 | Reported on November 9, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com EXHIBIT 99.2 Safe Harbor Statements © 2023 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs,

November 9, 2023 EX-99.1

The Joint Corp. Reports Third Quarter 2023 Financial Results - Reaffirms 2023 Financial and Clinic Opening Guidance - - Unveils Plan to Convert the Majority of the Corporate Portfolio Clinics to Franchised Clinics -

EXHIBIT 99.1 The Joint Corp. Reports Third Quarter 2023 Financial Results - Reaffirms 2023 Financial and Clinic Opening Guidance - - Unveils Plan to Convert the Majority of the Corporate Portfolio Clinics to Franchised Clinics - SCOTTSDALE, Ariz., November 9, 2023 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results

November 8, 2023 SC 13D/A

JYNT / Joint Corp / Bandera Partners LLC - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment

SC 13D/A 1 sc13da30870601311082023.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Cl

November 8, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 The Joint Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or other jurisdiction (Commission File Number) (IRS Employer o

November 8, 2023 EX-10.2

Confidentiality Agreement

EXHIBIT 10.2 CONFIDENTIALITY AGREEMENT November 6, 2023 Bandera Master Fund L.P. 50 Broad Street, Suite 1820 New York, New York 10004 Attention: Jefferson Gramm Dear Mr. Gramm: Reference is made to the Nomination and Standstill Agreement (as the same may be amended, the “Nomination and Standstill Agreement”), dated as of November 6, 2023, by and among The Joint Corp., a Delaware corporation (toget

November 8, 2023 EX-10.1

Nomination and Standstill Agreement, dated November

EXHIBIT 10.1 NOMINATION AND STANDSTILL AGREEMENT This Nomination and Standstill Agreement (as the same may be amended, this “Agreement”), dated as of November 6, 2023 (the “Effective Date”), is by and among The Joint Corp., a Delaware corporation (the “Company”), and the Persons (as defined below) set forth on the signature pages hereto (collectively “Bandera”). Capitalized terms used in this Agre

November 8, 2023 EX-99.1

The Joint Corp. Welcomes Jeff Gramm to the Board of Directors and Signs Standstill Agreement with Bandera Partners LLC

EXHIBIT 99.1 The Joint Corp. Welcomes Jeff Gramm to the Board of Directors and Signs Standstill Agreement with Bandera Partners LLC SCOTTSDALE, Ariz., November 8, 2023 – The Joint Corp. (NASDAQ: JYNT), the nation’s largest provider of chiropractic care through The Joint Chiropractic® network, will appoint Jeff Gramm to the board of directors, effective January 2, 2024 and nominate him for election

November 8, 2023 EX-99.1

NOMINATION AND STANDSTILL AGREEMENT

EX-99.1 2 ex991to13da308706013110823.htm NOMINATION AND STANDSTILL AGREEMENT, DATED NOVEMBER 6, 2023 Exhibit 99.1 NOMINATION AND STANDSTILL AGREEMENT This Nomination and Standstill Agreement (as the same may be amended, this “Agreement”), dated as of November 6, 2023 (the “Effective Date”), is by and among The Joint Corp., a Delaware corporation (the “Company”), and the Persons (as defined below)

October 30, 2023 EX-10.16

Executive Short-Term Incentive Plan (STIP) (Amended March 7, 2023)

10.16 The Joint Corp. Executive Short-Term Incentive Plan (STIP) (Amended March 7, 2023) Plan Overview The Joint Corp. (“the Company”) Executive Short-Term Incentive Plan (“Executive STIP”) is an annual bonus plan. The STIP pool earned for each year will be determined based upon the achievement of the Company’s Target EBITDA for that year. Upon achievement of the Target EBITDA for the calendar yea

October 30, 2023 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joi

September 26, 2023 EX-10.25

Form of the Registrant’s Franchise Agreement.

10.25 THE JOINT CORP. FRANCHISE AGREEMENT TABLE OF CONTENTS SECTION PAGE TOC \h \u \z 1. INTRODUCTION……………………………………………………………………………………4 2. GRANT OF FRANCHISE…………………………………………………………………………...5 2.1 Term; Reference to Exhibit 1………………………………………………………………………5 2.2 Full Term Performance…………………………………………………………………………….6 2.3 Management Agreement with Professional Corporation – Non-Licensed Franchisees…………...6 2.4

September 26, 2023 EX-10.24

Form of the Registrant’s Regional Developer License Agreement.

10.24 THE JOINT CORP. REGIONAL DEVELOPER AGREEMENT Date of Agreement TABLE OF CONTENTS SECTION PAGE 1. GRANT OF RIGHTS………………………………………………………………………..…...1 2. REGIONAL DEVELOPER’S DEVELOPMENT OBLIGATION …………………................1 2.1 Minimum Development Obligations and Development Schedule ………...……….1 2.2 Regional Developer Sales Office and Opening …………………………..………..4 3. TERRITORIAL RIGHTS AND LIMITATIO

September 26, 2023 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1 to Form 10-K) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1 to Form 10-K) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

September 26, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

September 26, 2023 EX-3.2

Fourth Amended and Restated Bylaws

FOURTH AMENDED AND RESTATED Ex. 3.2 BYLAWS OF THE JOINT CORP. ARTICLE I Meetings of Stockholders Section 1.1 Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution or resolutions of the Board of Directors (th

September 25, 2023 SC 13D/A

JYNT / Joint Corp / Bandera Partners LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) JEFFERSON GRAMM BANDERA PARTNER

September 15, 2023 8-K/A

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 30, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation)

September 15, 2023 SC 13D/A

JYNT / Joint Corp / Bandera Partners LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) JEFFERSON GRAMM BANDERA PARTNER

September 13, 2023 EX-99.1

The Joint Corp. Reports Preliminary Second Quarter 2023 Financial Results - Grew Q2 2023 Preliminary Revenue 18% and Preliminary Adjusted EBITDA 23% vs. Q2 2022 - - Evaluating Programs to Cull Approximately 10% of the Corporate Portfolio -

EXHIBIT 99.1 The Joint Corp. Reports Preliminary Second Quarter 2023 Financial Results - Grew Q2 2023 Preliminary Revenue 18% and Preliminary Adjusted EBITDA 23% vs. Q2 2022 - - Evaluating Programs to Cull Approximately 10% of the Corporate Portfolio - SCOTTSDALE, Ariz., Sept. 13, 2023 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic c

September 13, 2023 EX-99.2

Preliminary Q2 2023 Investor Presentation As of June 30, 2023 | Reported on September 13, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com Safe Harbor Statements © 2023 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this pre

Exhibit 99.2 Preliminary Q2 2023 Investor Presentation As of June 30, 2023 | Reported on September 13, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com Safe Harbor Statements © 2023 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs,

September 13, 2023 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File

September 12, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 6, 2023 The Joint Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 6, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation (Commission file n

September 6, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 The Joint Corp. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Nu

September 6, 2023 EX-99.1

The Joint Corp. Provides Updates on the June 30, 2023 SEC 10-Q Filing

EXHIBIT 99.1 The Joint Corp. Provides Updates on the June 30, 2023 SEC 10-Q Filing SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, announced the company intends to restate previously issued audited financial statements as of and for the year ending December 31, 2022 contained in the Annual Re

August 25, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 The Joint Corp. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Nu

August 25, 2023 EX-99.1

The Joint Corp. Announces Receipt of Delinquency Notification Letter from Nasdaq

EXHIBIT 99.1 The Joint Corp. Announces Receipt of Delinquency Notification Letter from Nasdaq SCOTTSDALE, Ariz., Aug. 25, 2023 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, announced it received a delinquency notification letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) on

August 15, 2023 NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36724 CUSIP Number: 47973J102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

August 11, 2023 SC 13D

JYNT / Joint Corp / Bandera Partners LLC - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) JEFFERSON GRAMM BANDERA PARTNERS

August 11, 2023 EX-99.1

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the shares of Common Stock, $0.001 par value per share, of The Joint Corp. This Joint Filing Agreement shall be fi

August 10, 2023 EX-99.2

Q2 2023 Operating Highlights As of June 30, 2023 | Reported on August 10, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com 2 © 2023 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "f

EXHIBIT 99.2 Q2 2023 Operating Highlights As of June 30, 2023 | Reported on August 10, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com 2 © 2023 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and

August 10, 2023 EX-99.1

The Joint Corp. Reports Second Quarter 2023 Operating Highlights – System-wide Sales Grew 13% to $120.1 Million – – Unrestricted Cash $13.6 Million at June 30, 2023, Compared to $9.7 Million at December 31, 2022 – – Increased Clinics to 890 at June 3

EXHIBIT 99.1 The Joint Corp. Reports Second Quarter 2023 Operating Highlights – System-wide Sales Grew 13% to $120.1 Million – – Unrestricted Cash $13.6 Million at June 30, 2023, Compared to $9.7 Million at December 31, 2022 – – Increased Clinics to 890 at June 30, 2023 and Achieved the 900 Clinic Milestone in August 2023 – SCOTTSDALE, Ariz., Aug. 10, 2023 (GLOBE NEWSWIRE) - The Joint Corp. (NASDA

August 10, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 The Joint Corp. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Nu

May 26, 2023 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 25, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file numbe

May 25, 2023 S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 The Joint Corp. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 The Joint Corp.

May 25, 2023 EX-99.1

The Joint Corp. Amended and Restated 2014 Incentive Stock Plan, as amended

Exhibit 99.1 Amendment to The Joint Corp. Amended and Restated 2014 Incentive Stock Plan The first sentence of Section 4.3, Maximum Number of Shares, of the Amended and Restated 2014 Incentive Stock Plan, as amended (the “Plan”), is hereby deleted in its entirety and replaced with the following: The maximum total number of shares of common stock for which Awards may be granted under this Plan is 3

May 25, 2023 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) The Joint Corp. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $.00

May 5, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

May 5, 2023 EX-10.16

Executive Short-Term Incentive Plan (amended March 7, 2023).

10.16 The Joint Corp. Executive Short-Term Incentive Plan (STIP) (Amended March 7, 2023) Plan Overview The Joint Corp. (“the Company”) Executive Short-Term Incentive Plan (“Executive STIP”) is an annual bonus plan. The STIP pool earned for each year will be determined based upon the achievement of the Company’s Target EBITDA for that year. Upon achievement of the Target EBITDA for the calendar yea

May 4, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 The Joint Corp. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Number

May 4, 2023 EX-99.2

Q1 2023 Financial Results As of March 31, 2023 | Reported on May 4, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com 2 © 2023 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward

Exhibit 99.2 Q1 2023 Financial Results As of March 31, 2023 | Reported on May 4, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com 2 © 2023 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expec

May 4, 2023 EX-99.1

The Joint Corp. Reports First Quarter 2023 Financial Results - Grew Q1 2023 Revenue 27%, System-wide Sales 17% and System-wide Comp Sales 8% vs. Q1 2022 - - Increased Clinic Count to 870, Including 130 Company-Owned or Managed Clinics, at March 31, 2

EXHIBIT 99.1 The Joint Corp. Reports First Quarter 2023 Financial Results - Grew Q1 2023 Revenue 27%, System-wide Sales 17% and System-wide Comp Sales 8% vs. Q1 2022 - - Increased Clinic Count to 870, Including 130 Company-Owned or Managed Clinics, at March 31, 2023 - SCOTTSDALE, Ariz., May 04, 2023 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of

April 26, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 20, 2023 The Joint Corp. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 20, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file num

April 26, 2023 EX-3.2

Third Amended and Restated Bylaws of The Joint Corp. (incorporated by reference to Exhibit 3. to the Company’s Current Report on Form 8-K (Commission File No. 001-36724) filed with the Securities and Exchange Commission on April 26, 2023

Exhibit 3.2 Third Amended and Restated Bylaws of The Joint Corp. (Amended and Restated as of April 20, 2023) Table of Contents Article 1 Offices 4 1.1 Registered Office 4 1.2 Other Offices 4 Article 2 Stockholders 4 2.1 Annual Meeting 4 2.2 Business at Annual Meetings of Stockholders 4 2.3 Proxy Access for Director Nominations 6 2.4 Special Meetings 12 2.5 Place of Meetings 13 2.6 Notice of Meetin

April 21, 2023 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

March 13, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 The Joint Corp. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Numb

March 13, 2023 EX-99.1

The Joint Corp. Thanks Retiring Board Member James H. Amos, Jr.

EXHIBIT 99.1 The Joint Corp. Thanks Retiring Board Member James H. Amos, Jr. SCOTTSDALE, Ariz., March 13, 2023 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, announced James H. Amos, Jr. has notified the company that he will complete his term on May 25, 2023 and not stand for reelection at the company’s 2023 Annual Meeting o

March 10, 2023 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36724 The Joint Corp. (Exact na

March 10, 2023 EX-10.25

Form of Registrant’s Franchise Agreement.

10.25 THE JOINT CORP. FRANCHISE AGREEMENT TABLE OF CONTENTS SECTION PAGE TOC \h \u \z 1. INTRODUCTION……………………………………………………………………………………4 2. GRANT OF FRANCHISE…………………………………………………………………………...5 2.1 Term; Reference to Exhibit 1………………………………………………………………………5 2.2 Full Term Performance…………………………………………………………………………….6 2.3 Management Agreement with Professional Corporation – Non-Licensed Franchisees…………...6 2.4

March 10, 2023 EX-10.24

Form of Registrant’s Regional Developer License Agreement.

10.24 THE JOINT CORP. REGIONAL DEVELOPER AGREEMENT Date of Agreement TABLE OF CONTENTS SECTION PAGE 1. GRANT OF RIGHTS………………………………………………………………………..…...1 2. REGIONAL DEVELOPER’S DEVELOPMENT OBLIGATION …………………................1 2.1 Minimum Development Obligations and Development Schedule ………...……….1 2.2 Regional Developer Sales Office and Opening …………………………..………..4 3. TERRITORIAL RIGHTS AND LIMITATIO

March 9, 2023 EX-99.1

The Joint Corp. Reports Fourth Quarter and Year-end 2022 Financial Results - Grew Q4 2022 Revenue 26%, System-wide Sales 18%, and System-wide Comp Sales 8% vs. Q4 2021 - - Increased Clinic Count to 838 at Year-end 2022, Including 126 Company-Owned or

EXHIBIT 99.1 The Joint Corp. Reports Fourth Quarter and Year-end 2022 Financial Results - Grew Q4 2022 Revenue 26%, System-wide Sales 18%, and System-wide Comp Sales 8% vs. Q4 2021 - - Increased Clinic Count to 838 at Year-end 2022, Including 126 Company-Owned or Managed Clinics - SCOTTSDALE, Ariz., March 09, 2023 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and

March 9, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 The Joint Corp. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Numb

March 9, 2023 EX-99.2

Q4 2022 Financial Results As of December 31, 2022 | Reported on March 9, 2023 2 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statem

Exhibit 99.2 Q4 2022 Financial Results As of December 31, 2022 | Reported on March 9, 2023 2 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our gr

February 13, 2023 SC 13G/A

JYNT / Joint Corp / Bandera Partners LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga208706jynt02132023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par valu

February 9, 2023 SC 13G/A

JYNT / Joint Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Joint Corp. Title of Class of Securities: Common Stock CUSIP Number: 47973J102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

January 13, 2023 CORRESP

The Joint Corp. 16767 N. Perimeter Drive, Suite 110 Scottsdale, AZ 85260 January 13, 2023

CORRESP 1 filename1.htm The Joint Corp. 16767 N. Perimeter Drive, Suite 110 Scottsdale, AZ 85260 January 13, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, NE Washington, D.C. 20549-3561 Attention: Ameen Hamady or Kristi Marrone Re: The Joint Corp. Form 10-K for the year ended December 31, 2021 Filed March 1

January 13, 2023 SC 13G

JYNT / Joint Corp / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G 1 JYNTSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 THE JOINT CORP. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 47973J102 (CUSIP Number) JANUARY 4, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule

November 4, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The J

November 3, 2022 EX-99.1

The Joint Corp. Reports Third Quarter 2022 Financial Results - Grew Revenue 27%, System-wide Sales 18%, and System-wide Comp Sales 6% vs. Q3 2021 - - Opened 38 Clinics, Up from 33 in Q3 2021 - Surpassed 800 Clinic Milestone, Closing Q3 2022 with 805

EXHIBIT 99.1 The Joint Corp. Reports Third Quarter 2022 Financial Results - Grew Revenue 27%, System-wide Sales 18%, and System-wide Comp Sales 6% vs. Q3 2021 - - Opened 38 Clinics, Up from 33 in Q3 2021 - Surpassed 800 Clinic Milestone, Closing Q3 2022 with 805 Clinics, Including 115 Company-Owned or Managed Clinics - SCOTTSDALE, Ariz., Nov. 03, 2022 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JY

November 3, 2022 EX-99.2

Q3 2022 Financial Results As of September 30 , 2022 | Reported on November 3, 2022 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking sta

EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 Q3 2022 Financial Results As of September 30 , 2022 | Reported on November 3, 2022 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial

November 3, 2022 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File N

August 5, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

August 5, 2022 EX-10.1

Asset and Franchise Purchase Agreement dated May 19, 2022 among the Company, SJV Tempe Marketplace, LLC, an Arizona limited liability company (“ TM ”), Shakarian Joint Ventures, LLC, an Arizona limited liability company (“ SJV ”), SJV East Mesa, LLC, an Arizona limited liability company (“ EM ”), SJV Apache Junction, LLC, an Arizona limited liability company (“ AJ ”), Dr. Aaron Shakarian, an individual and Stacie Shakarian, an individual (TM, SJV, EM, AJ, Dr. Aaron Shakarian and Stacie Shakarian, collectively, the “Seller ”), and Shakarian Holdings, LLC, an Arizona limited liability company, Dr. Aaron Shakarian, an individual and Stacie Shakarian, an individual (collectively, the “ Shareholder ”)

Ex. 10.1 ASSET AND FRANCHISE AGREEMENT PURCHASE AGREEMENT THIS ASSET AND FRANCHISE AGREEMENT PURCHASE AGREEMENT (?Agreement?) is made and entered into on the date last set forth below on the signature page (?Effective Date?), by and between The Joint Corp., a Delaware corporation (?TJC?), SJV Tempe Marketplace, LLC, an Arizona limited liability company (?TM?), Shakarian Joint Ventures, LLC, an Ari

August 4, 2022 EX-99.2

Q2 2022 Financial Results As of June 30 , 2022 | Reported on August 4, 2022 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements

Exhibit 99.2 Q2 2022 Financial Results As of June 30 , 2022 | Reported on August 4, 2022 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements? about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth

August 4, 2022 EX-99.1

The Joint Corp. Reports Second Quarter 2022 Financial Results - Grew Revenue 24%, System-wide Sales 21%, and System-wide Comp Sales 8% vs. Q2 2021 - - Opened 34 Clinics, Bringing Total Clinics to 769 - - Sold 24 Franchise Licenses, Bringing the Year-

EXHIBIT 99.1 The Joint Corp. Reports Second Quarter 2022 Financial Results - Grew Revenue 24%, System-wide Sales 21%, and System-wide Comp Sales 8% vs. Q2 2021 - - Opened 34 Clinics, Bringing Total Clinics to 769 - - Sold 24 Franchise Licenses, Bringing the Year-to-Date Total to 46 - SCOTTSDALE, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager, a

August 4, 2022 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Num

June 10, 2022 SC 13G/A

JYNT / Joint Corp / ALGER ASSOCIATES INC - THE JOINT CORP. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* The Joint Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 47973J102 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

May 31, 2022 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 26, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other juris- (Commission file (IRS employer diction of inco

May 23, 2022 8-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

May 23, 2022 EX-99.1

The Joint Corp. Acquires Four Previously Owned Franchised Clinics, Strengthening the Scottsdale/Phoenix Region Cluster - Expected to be immediately accretive to the bottom line and improve the corporate clinic operating margin -

EXHIBIT 99.1 The Joint Corp. Acquires Four Previously Owned Franchised Clinics, Strengthening the Scottsdale/Phoenix Region Cluster - Expected to be immediately accretive to the bottom line and improve the corporate clinic operating margin - SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chirop

May 10, 2022 SC 13G/A

JYNT / Joint Corp / Bandera Partners LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) May 6, 2022 (Date

May 6, 2022 EX-10.1

Corrected Second Amendment to Credit Agreement, dated as of February 28, 2022 (the “2022 Amendment”) with Annex 1 Credit

EX-10.1 2 exhibit101.htm EX-10.1 10.1 EXECUTION VERSION SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made as of February 28, 2022 (the “Second Amendment Effective Date”), by and among THE JOINT CORP., a Delaware corporation (“Borrower”), the other Loan Parties party hereto (“Loan Parties”), the Lenders party hereto (the “Lenders”), and JPMORG

May 6, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

May 5, 2022 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Number

May 5, 2022 EX-99.2

Q1 2022 Financial Results As of March 31, 2022 | Reported on May 5, 2022 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements ar

Exhibit 99.2 Q1 2022 Financial Results As of March 31, 2022 | Reported on May 5, 2022 Safe Harbor Statements Certain statements contained in this presentation are "forward - looking statements? about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth pl

May 5, 2022 EX-99.1

The Joint Corp. Reports First Quarter 2022 Financial Results - Grew Revenue 28%, System-wide Sales 27%, and System-wide Comp Sales 15%, Versus Q1 2021 - - Opened 31 Clinics, Including 27 Franchised - the Most for a First Quarter in the Company’s Hist

EXHIBIT 99.1 The Joint Corp. Reports First Quarter 2022 Financial Results - Grew Revenue 28%, System-wide Sales 27%, and System-wide Comp Sales 15%, Versus Q1 2021 - - Opened 31 Clinics, Including 27 Franchised - the Most for a First Quarter in the Company?s History - - Achieved Milestone of 100 Corporate Portfolio Clinics, Bringing Total Clinics to 736 - SCOTTSDALE, Ariz., May 05, 2022 (GLOBE NEW

April 22, 2022 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 def14a041922.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

March 14, 2022 EX-10.5

Amendment to Amended and Restated 2014 Incentive Stock Plan

10.5 Amendment to The Joint Corp. Amended and Restated 2014 Incentive Stock Plan (effective with respect to Awards issued on or after November 2, 2021) 1.The following shall be added to Article 2 of the Amended and Restated 2014 Incentive Stock Plan, as amended (the ?Plan?), immediately following the definition of ?SAR Award?: Section 16 Officer means an ?officer? as defined by Rule 16a-1 promulga

March 14, 2022 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36724 The Joint Corp. (Exact na

March 14, 2022 EX-10.19

Form of Registrant’s Regional Developer Franchise Disclosure Document - 2021

THE JOINT ? ? RD FDD 2021 FRANCHISE DISCLOSURE DOCUMENT The Joint Corp. 16767 N. Perimeter Dr., Suite 110 Scottsdale, Arizona 85260 Telephone (480) 245-5960 Website: www.thejoint.com Email: [email protected] This disclosure document is for the right to own and operate a Regional Developer Business in which you will be responsible for promoting, establishing and supporting Location Franchises

March 14, 2022 EX-10.2

Form of Registrant’s Unit Franchise Disclosure Document - 2021

{WS087179v1 } 1 FRANCHISE DISCLOSURE DOCUMENT The Joint Corp. 16767 N. Perimeter Dr., Suite 110 Scottsdale, Arizona 85260 Telephone (480) 245-5960 Website: www.thejoint.com Email: [email protected] This disclosure document is for the right to own and operate a franchise (?Location Franchise?) in which you will be responsible for operating and/or managing chiropractic clinics (?Clinic(s)?) th

March 11, 2022 SC 13G

JYNT / Joint Corp / Bandera Partners LLC - THE SCHEDULE 13G Passive Investment

SC 13G 1 sc13g0870600203112022.htm THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Secu

March 11, 2022 EX-99.1

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 11, 2022 with respect to the Common Stock, $0.001 par value, of The Joint Corp, and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Secur

March 10, 2022 SC 13G/A

JYNT / Joint Corp / ALGER ASSOCIATES INC - THE JOINT CORP. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* The Joint Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 47973J102 (CUSIP Number) February 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

March 4, 2022 EX-10.1

Second Amendment to Credit Agreement, dated as of February 28, 2022 (the “2022 Amendment”) with Annex 1 Credit Agreement, among the Company, the Lenders Party Hereto, and JPMorgan Chase Bank, N.A., as Administrative Agent and Sole Bookrunner and Sole Lead Arranger

Exhibit 10.1 E X E CU T I ON V E R S I ON SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this ?Amendment? ) is made as of February 28 , 2020 (the ?Second Amendment Effective Date? ), by and among THE JOINT CORP . , a Delaware corporation ( ?Borrower? ), the other Loan Parties party hereto (? Loan Parties ?), the Lenders party hereto (the ? Lenders ?), and JPMORGAN

March 4, 2022 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 28, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file

March 4, 2022 EX-10.2

Amended and Restated Revolving Loan Note dated February 28, 2022

Exhibit 10.2 EXECUTION VERSION REVOLVING LOAN NOTE $20,000,000 Chicago, Illinois February 28, 2022 FOR VALUE RECEIVED, the undersigned THE JOINT CORP., a Delaware corporation (herein, together with its successors and assigns, the ?Borrower?), hereby promises to pay to JPMORGAN CHASE BANK, N.A. (the ?Lender?) or its registered assignees, in lawful money of the United States of America and in immedi

March 2, 2022 NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-K 1 fnt10k030222.htm FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36724 CUSIP Number: 47973J102 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-

February 25, 2022 8-K/A

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 24, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission fil

February 25, 2022 EX-99.1

UPDATE -- The Joint Corp. Reports Preliminary Fourth Quarter and Year-end 2021 Financial Results - Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 - - Sold 156 Franchise Licenses, Compared to 121 in 202

EXHIBIT 99.1 UPDATE - The Joint Corp. Reports Preliminary Fourth Quarter and Year-end 2021 Financial Results - Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 - - Sold 156 Franchise Licenses, Compared to 121 in 2020 - - Opened 130 Clinics, Including 20 Greenfields, Bringing the Total Corporate Count to 96 at Year End - SCOTTSDALE, Ariz., Feb. 24, 202

February 24, 2022 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File

February 24, 2022 EX-99.2

© 2022 The Joint Corp. All Rights Reserved. 1 Q4 2021 Preliminary Financial Results As of December 31, 2021 | Reported on February 24, 2022 Safe Harbor Statement © 2022 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this prese

EXHIBIT 99.2 ? 2022 The Joint Corp. All Rights Reserved. 1 Q4 2021 Preliminary Financial Results As of December 31, 2021 | Reported on February 24, 2022 Safe Harbor Statement ? 2022 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements? about future events and expectations. Forward - looking statements are based on our beliefs, a

February 24, 2022 EX-99.1

The Joint Corp. Reports Preliminary Fourth Quarter and Year-end 2021 Financial Results - Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 - - Sold 156 Franchise Licenses, Compared to 121 in 2020 - - Open

EXHIBIT 99.1 The Joint Corp. Reports Preliminary Fourth Quarter and Year-end 2021 Financial Results - Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 - - Sold 156 Franchise Licenses, Compared to 121 in 2020 - - Opened 130 Clinics, Including 20 Greenfields, Bringing the Total Corporate Count to 96 at Year End - SCOTTSDALE, Ariz., Feb. 24, 2022 (GLOBE

February 14, 2022 EX-1

EXHIBIT 1: Joint Filing Agreement (filed herewith):

SW Investment Management LLC SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.

February 14, 2022 SC 13G/A

JYNT / Joint Corp / SW Investment Management LLC - AMENDMENT TO FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Joint Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 47973J102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

February 14, 2022 SC 13G/A

JYNT / Joint Corp / Bandera Partners LLC - AMENDMENT NO. 5 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) December 31, 2021

February 14, 2022 SC 13G/A

JYNT / Joint Corp / ALGER ASSOCIATES INC - THE JOINT CORP. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Joint Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 47973J102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

February 10, 2022 SC 13G

JYNT / Joint Corp / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv01230-jointcorp.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Joint Corp. Title of Class of Securities: Common Stock CUSIP Number: 47973J102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sche

November 5, 2021 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The J

November 4, 2021 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File N

November 4, 2021 EX-99.2

© 2021 The Joint Corp. All Rights Reserved. 1 Q3 2021 Financial Results As of September 30, 2021 | Reported on November 4, 2021 Safe Harbor Statement © 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are

EX-99.2 3 exh992.htm PRESENTATION Exhibit 99.2 © 2021 The Joint Corp. All Rights Reserved. 1 Q3 2021 Financial Results As of September 30, 2021 | Reported on November 4, 2021 Safe Harbor Statement © 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are b

November 4, 2021 EX-99.1

The Joint Corp. Reports Third Quarter 2021 Financial Results - Grows Revenue 36%, System-wide Sales 37%, and System-wide Comp Sales 27%, Compared to Q3 2020 - - Sold 44 Franchise Licenses, Compared to 30 in Q3 2020 - - Opened 33 Clinics, Including 5

EXHIBIT 99.1 The Joint Corp. Reports Third Quarter 2021 Financial Results - Grows Revenue 36%, System-wide Sales 37%, and System-wide Comp Sales 27%, Compared to Q3 2020 - - Sold 44 Franchise Licenses, Compared to 30 in Q3 2020 - - Opened 33 Clinics, Including 5 Greenfields, Bringing the Total Corporate Count to 83 at Quarter End - - Raised 2021 Guidance on Franchise Openings, Revenue and Adjusted

October 8, 2021 SC 13G/A

JYNT / Joint Corp / ALGER ASSOCIATES INC - THE JOINT CORP. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* The Joint Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 47973J102 (CUSIP Number) September 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu

August 6, 2021 EX-10.1

Executive Short-Term Incentive Plan (amended May 2, 2021).

The Joint Corp. Executive Short-Term Incentive Plan (STIP) (Amended May 2, 2021) Plan Overview The Joint Corp. (?the Company?) Executive Short-Term Incentive Plan (?Executive STIP?) is an annual bonus plan. The STIP pool earned for each year will be determined based upon the achievement of the Company?s Target EBITDA for that year. Upon achievement of the Target EBITDA for the calendar year, each

August 6, 2021 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

August 5, 2021 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Num

August 5, 2021 EX-99.2

© 2021 The Joint Corp. All Rights Reserved. 1 Q2 2021 Financial Results As of June 30, 2021 | Reported on August 5, 2021 Safe Harbor Statement © 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forwar

Exhibit 99.2 ? 2021 The Joint Corp. All Rights Reserved. 1 Q2 2021 Financial Results As of June 30, 2021 | Reported on August 5, 2021 Safe Harbor Statement ? 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements? about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expe

August 5, 2021 EX-99.1

The Joint Corp. Reports Second Quarter 2021 Record Financial Results, Raises All Elements of Guidance - Grows Revenue 61%, System-wide Sales 64%, and System-wide Comp Sales 53%, Compared to Q2 2020 - - Reports Operating Income of $2.0 Million, Up 687

EXHIBIT 99.1 The Joint Corp. Reports Second Quarter 2021 Record Financial Results, Raises All Elements of Guidance - Grows Revenue 61%, System-wide Sales 64%, and System-wide Comp Sales 53%, Compared to Q2 2020 - - Reports Operating Income of $2.0 Million, Up 687% Compared to Q2 2020 - - Posts Adjusted EBITDA of $3.8 Million, Up 237% Compared to Q2 2020 - SCOTTSDALE, Ariz., Aug. 05, 2021 (GLOBE NE

July 9, 2021 SC 13G

JYNT / Joint Corp / ALGER ASSOCIATES INC - THE JOINT CORP. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* The Joint Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 47973J102 (CUSIP Number) June 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

June 17, 2021 SC 13G/A

JYNT / Joint Corp / Bandera Partners LLC - AMENDMENT NO. 4 TO THE SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga40870600206172021.htm AMENDMENT NO. 4 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value

June 2, 2021 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 28, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file numbe

May 7, 2021 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 3, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file number

May 7, 2021 10-Q

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

May 6, 2021 EX-99.1

The Joint Corp. Reports First Quarter 2021 Financial Results - Grows Revenue 29%, System-wide Sales 28%, and System-wide Comp Sales 21%, Compared to Q1 2020 - - Reports Operating Income of $2.0 Million, Up 162% Compared to Q1 2020 - - Posts Adjusted

EXHIBIT 99.1 The Joint Corp. Reports First Quarter 2021 Financial Results - Grows Revenue 29%, System-wide Sales 28%, and System-wide Comp Sales 21%, Compared to Q1 2020 - - Reports Operating Income of $2.0 Million, Up 162% Compared to Q1 2020 - - Posts Adjusted EBITDA of $3.5 Million, Up 108% Compared to Q1 2020 - - Raises 2021 Revenue and Adjusted EBITDA Guidance - SCOTTSDALE, Ariz., May 06, 202

May 6, 2021 EX-99.2

© 2021 The Joint Corp. All Rights Reserved. 1 Q1 2021 Financial Results As of March 31, 2021 | Reported on May 6, 2021 Safe Harbor Statement © 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward

EXHIBIT 99.2 ? 2021 The Joint Corp. All Rights Reserved. 1 Q1 2021 Financial Results As of March 31, 2021 | Reported on May 6, 2021 Safe Harbor Statement ? 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements? about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expect

May 6, 2021 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Number

April 23, 2021 DEF 14A

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

April 21, 2021 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 15, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file num

March 30, 2021 EX-16.1

Letter from Plante & Moran, PLLC, dated as of March 30, 2021

Exhibit 16.1 March 30, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by The Joint Corp. and are in agreement with the statements contained in Item 4.01(a) therein, which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01(a) of Form 8-K of The Joint Corp. dated March 30, 202

March 30, 2021 8-K

Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 29, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other jurisdiction of incorporation) (Commission file num

March 5, 2021 10-K

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36724 The Joint Corp. (Exact na

March 5, 2021 EX-10.4

North Carolina Regional Developer License Purchase Agreement dated as of December 31, 2020 by and among the Company as purchaser, Wellness Incorporated, a North Carolina corporation as seller, and Paul Trindel as guarantor

10.40 North Carolina Regional Developer License Purchase Agreement This North Carolina Regional Developer License Purchase Agreement (this ?Agreement?) is entered into on the date last set forth below on the signature page (the ?Effective Date?), by and between The Joint Corp., a Delaware corporation (?TJC?), Wellness Incorporated, a North Carolina corporation (?Seller?), and Paul Trindel (?Guaran

March 5, 2021 EX-10.41

Georgia Regional Developer License Purchase Agreement dated as of January 1, 2021 by and among the Company as purchaser, Midtown Health Solutions, Inc., a Georgia corporation as seller, and Dr. Patrick Greco as guarantor

10.41 Georgia Regional Developer License Purchase Agreement This Georgia Regional Developer License Purchase Agreement (this ?Agreement?) is entered into on January 1, 2021 (the ?Effective Date?), by and between The Joint Corp., a Delaware corporation (?TJC?), Midtown Health Solutions, Inc., a Georgia corporation (?Seller?), and Dr. Patrick Greco (?Guarantor?). TJC, Seller and Guarantor are at tim

March 4, 2021 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Numb

March 4, 2021 EX-99.2

© 2021 The Joint Corp. All Rights Reserved. 1 Q4 2020 Financial Results As of December 31, 2020 | Reported on March 4, 2021 Safe Harbor Statement © 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "for

Exhibit 99.2 ? 2021 The Joint Corp. All Rights Reserved. 1 Q4 2020 Financial Results As of December 31, 2020 | Reported on March 4, 2021 Safe Harbor Statement ? 2021 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements? about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and e

March 4, 2021 EX-99.1

The Joint Corp. Reports Fourth Quarter and Full Year 2020 Financial Results - Grows Revenue 23% Quarterly and 21% Annually, Compared to 2019 - - Reports Record Annual Operating Income of $5.5 Million, Up 61% Compared to 2019 - - Posts Record Adjusted

EXHIBIT 99.1 The Joint Corp. Reports Fourth Quarter and Full Year 2020 Financial Results - Grows Revenue 23% Quarterly and 21% Annually, Compared to 2019 - - Reports Record Annual Operating Income of $5.5 Million, Up 61% Compared to 2019 - - Posts Record Adjusted EBITDA of $9.1 Million, Up 47% Compared to 2019 - - Increases Total Clinic Count to 579, Opening 21 Clinics in Q4 2020, Compared to 25 i

February 12, 2021 SC 13G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) December 31, 2020

February 12, 2021 EX-1

Joint Filing Agreement (filed herewith):

EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT SW Investment Management LLC SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filin

February 12, 2021 SC 13G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) (CUSIP Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

February 12, 2021 SC 13G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* The Joint Corp. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 47973J102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

January 27, 2021 EX-10.1

Executive Short-Term Incentive Plan (amended January 25, 2021) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (Commission File No. 001-36724) filed with the Securities and Exchange Commission on January 27, 2021)

Exhibit 10.1 The Joint Corp. Executive Short-Term Incentive Plan (STIP) (Amended January 25, 2021) Plan Overview The Joint Corp. (“the Company”) Executive Short-Term Incentive Plan (“Executive STIP”) is an annual bonus plan. The STIP pool earned for each year will be determined based upon the achievement of the Company’s Target EBITDA for that year. Upon achievement of the Target EBITDA for the ca

January 27, 2021 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 25, 2021 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other juris- diction of incorporation) (Commission file

January 5, 2021 8-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File

January 5, 2021 EX-99.1

The Joint Corp. Acquires Two Regional Developer Territories - Increases Margin Contribution to the Company –

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 The Joint Corp. Acquires Two Regional Developer Territories - Increases Margin Contribution to the Company – SCOTTSDALE, Ariz., Jan. 05, 2021 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, acquired for $2.4 million the regional developer (RD) territories in North Carolina and in

November 6, 2020 10-Q

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The J

November 5, 2020 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File N

November 5, 2020 EX-99.2

© 2020 The Joint Corp. All Rights Reserved. 1 Q3 2020 Financial Results As of September 30, 2020 | Reported on November 5, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are

Exhibit 99.2 © 2020 The Joint Corp. All Rights Reserved. 1 Q3 2020 Financial Results As of September 30, 2020 | Reported on November 5, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements." We have tried to identify these forward - look ing statements by using words such as "may," "might," " wi

November 5, 2020 EX-99.1

The Joint Corp. Reports Third Quarter 2020 Financial Results - Grows Revenue 21%, Compared to Q3 2019 – - Reports Record Net Income of $1.6 Million, Up 160% Compared to Q3 2019 – - Posts Record Adjusted EBITDA of $2.6 Million, Up 84% Compared to Q3 2

EXHIBIT 99.1 The Joint Corp. Reports Third Quarter 2020 Financial Results - Grows Revenue 21%, Compared to Q3 2019 – - Reports Record Net Income of $1.6 Million, Up 160% Compared to Q3 2019 – - Posts Record Adjusted EBITDA of $2.6 Million, Up 84% Compared to Q3 2019 - - Increases Total Clinic Count to 560, Opening 22 Clinics in Q3 2020- - Sells 30 Franchise Licenses in Q3 2020, Up from 28 in Q3 20

September 21, 2020 SC 13G

JYNT / The Joint Corp. / SW Investment Management LLC - ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment

SC 13G 1 swim-sc13g090920.htm ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 0)* The Joint Corp. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 47973J102 (CUSIP Number) September 9, 2020 (Date of Event Which Requires Filing of

August 10, 2020 8-K/A

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 29, 2020 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other juris- (Commission file (IRS empl

August 7, 2020 10-Q

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

August 6, 2020 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2020 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Number)

August 6, 2020 EX-99.2

© 2020 The Joint Corp. All Rights Reserved. 1 Q2 2020 Financial Results As of June 30, 2020 | Reported on August 6, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forwar

Exhibit 99.2 © 2020 The Joint Corp. All Rights Reserved. 1 Q2 2020 Financial Results As of June 30, 2020 | Reported on August 6, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements." We have tried to identify these forward - look ing statements by using words such as "may," "might," " will," "e

August 6, 2020 EX-99.1

The Joint Corp. Reports Second Quarter 2020 Financial Results - Grows Revenue 13%, Compared to Q2 2019 - - Increases Total Clinic Count to 539, Opening 13 Clinics in Q2 2020 - - Sells 11 Franchise Licenses in Q2 2020 -

EXHIBIT 99.1 The Joint Corp. Reports Second Quarter 2020 Financial Results - Grows Revenue 13%, Compared to Q2 2019 - - Increases Total Clinic Count to 539, Opening 13 Clinics in Q2 2020 - - Sells 11 Franchise Licenses in Q2 2020 - SCOTTSDALE, Ariz., Aug. 06, 2020 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, reported its fi

June 2, 2020 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 29, 2020 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other juris- (Commission file (IRS employer diction of inco

May 8, 2020 10-Q

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36724 The Joint

May 7, 2020 EX-99.1

The Joint Corp. Reports First Quarter 2020 Financial Results - Grows System-Wide Sales 24% and Comp Sales 15%, Compared to Q1 2019 - - Increases Total Clinic Count to 530 - - Sells 24 Franchise Licenses -

EXHIBIT 99.1 The Joint Corp. Reports First Quarter 2020 Financial Results - Grows System-Wide Sales 24% and Comp Sales 15%, Compared to Q1 2019 - - Increases Total Clinic Count to 530 - - Sells 24 Franchise Licenses - SCOTTSDALE, Ariz., May 07, 2020 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, reported its financial results

May 7, 2020 EX-99.2

© 2020 The Joint Corp. All Rights Reserved. 1 Q1 2020 Financial Results As of March 31, 2020 | Reported On May 7, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward

EXHIBIT 99.2 © 2020 The Joint Corp. All Rights Reserved. 1 Q1 2020 Financial Results As of March 31, 2020 | Reported On May 7, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements." We have tried to identify these forward - look ing statements by using words such as "may," "might," " will," "exp

May 7, 2020 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 7, 2020 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

April 24, 2020 DEF 14A

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

April 15, 2020 EX-10.1

Loan Note dated as of April 9, 2020 (incorporated by reference to the Company’s Current Report on Form 8-K (Commission File No. 001-36724) filed with the Securities and Exchange Commission on April 15, 2020)

Exhibit 10.1 NO TE Date 4/9/2020 Note Amount $ 2,727,970.00 Borrower The Joint Corporation Lender JPMorgan Chase Bank, N.A. 1. PROMISE TO PAY. Borrower promises to pay to the order of Lender the Note Amount, plus interest on the unpaid principal balance at the Note Rate, and all other amounts required by this Note. 2. DEFINITIONS. “CARES Act” means the Coronavirus Aid, Relief, and Economic Securit

April 15, 2020 8-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 f8k041520.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 9, 2020 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporati

April 15, 2020 EX-99.1

The Joint Chiropractic Secures $2.7 Million Loan under CARES Act Paycheck Protection Program Provision To Host First Quarter 2020 Results Conference Call on Thursday, May 7th

EX-99.1 3 exh991.htm PRESS RELEASE EXHIBIT 99.1 The Joint Chiropractic Secures $2.7 Million Loan under CARES Act Paycheck Protection Program Provision To Host First Quarter 2020 Results Conference Call on Thursday, May 7th SCOTTSDALE, Ariz., April 15, 2020 (GLOBE NEWSWIRE) - The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, announced it received a

March 20, 2020 8-K

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 18, 2020 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other juris- (Commission file (IRS employer diction of in

March 12, 2020 SC 13G/A

JYNT / The Joint Corp. / Bandera Partners LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 The Joint Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 47973J102 (CUSIP Number) March 10, 2020 (Da

March 6, 2020 EX-10.6

Amendment to Amended and Restated 2014 Incentive Stock Plan

Exhibit 10.6 Amendment to The Joint Corp. Amended and Restated 2014 Incentive Stock Plan (effective with respect to Awards issued on or after March 3, 2020) 1.Article 8 of the Amended and Restated 2014 Incentive Stock Plan (the “Plan”) is hereby deleted in its entirety and replaced with the following, effective for Awards issued on or after March 3, 2020: Article 8Change of Control; Dissolution or

March 6, 2020 EX-4.1

Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The Joint Corporation (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, par value $0.001 per share (the “common stock”). The common stock is listed on The NASDAQ C

March 6, 2020 EX-10.32

Amendment to Employment Letter Agreement between The Joint Corp. and Jake Singleton dated November 6, 2018

Exhibit 10.32 March 3, 2020 (retroactive to January 1, 2020) Mr. Jacob L. Singleton Dear Jake: This letter agreement (this “Amendment”) amends and extends your Employment Letter Agreement dated November 6, 2018 (the Letter Agreement, as so amended, the “Current Agreement”) with respect to your at-will employment arrangement as CFO. All capitalized terms used and not expressly defined herein shall

March 6, 2020 10-K

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36724 The Joint Corp. (Exact na

March 6, 2020 EX-10.16

2020 Amended Form of Restricted Stock Award Agreement under Amended and Restated 2014 Stock Plan

Exhibit 10.16 [[FIRSTNAME]] [[MIDDLENAME]] [[LASTNAME]] Restricted Stock Award (The Joint Corp. Amended and Restated 2014 Incentive Stock Plan) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as of the following grant date (the Grant Date), the following number of restricted shares (the Restricted Sha

March 6, 2020 EX-10.9

2020 Amended Form of Incentive Stock Option Agreement under Amended and Restated 2014 Stock Plan

Exhibit 10.9 [[FIRSTNAME]] [[MIDDLENAME]] [[LASTNAME]] ISO Stock Option Agreement (Incentive Stock Option Granted Under The Joint Corp. Amended and Restated 2014 Incentive Stock Plan) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as of the following grant date (the Grant Date), an incentive stock op

March 6, 2020 EX-10.12

Amended Form of Nonstatutory Stock Option Agreement under Amended and Restated 2014 Stock Plan

Exhibit 10.12 [[FIRSTNAME]] [[MIDDLENAME]] [[LASTNAME]] NSO Stock Option Agreement (Nonstatutory Stock Option Granted Under The Joint Corp. Amended and Restated 2014 Incentive Stock Plan) Subject to the following terms, The Joint Corp., a Delaware corporation (the Company), grants to the following employee of the Company (Grantee), as of the following grant date (the Grant Date), an nonstatutory s

March 6, 2020 EX-10.20

Lease Agreement dated May 17, 2019 between Registrant and Terra Verde Owner LLC for Registrant’s office located at 16767 North Perimeter Drive, Suite 110, Scottsdale, Arizona 85260

Exhibit 10.20 OFFICE LEASE AGREEMENT FOR TERRA VERDE AT SCOTTSDALE LANDING TERRA VERDE OWNER LLC, a Delaware limited liability company as Landlord and THE JOINT CORP., a Delaware corporation as Tenant Dated: May 17, 2019 (to be completed by Landlord upon Landlord’s execution of this Lease) 4824-0900-0329v5/27933-0139 OFFICE LEASE AGREEMENT THIS OFFICE LEASE AGREEMENT is made and entered into as of

March 5, 2020 EX-99.1

The Joint Corp. Reports Fourth Quarter and Full Year 2019 Financial Results - Grows Annual System-Wide Sales 33% and Comp Sales 25%, Compared to 2018 - - Increases Annual Net Income to $3.3 Million, Compared to $147,000 in 2018 - - More than Doubles

EXHIBIT 99.1 The Joint Corp. Reports Fourth Quarter and Full Year 2019 Financial Results - Grows Annual System-Wide Sales 33% and Comp Sales 25%, Compared to 2018 - - Increases Annual Net Income to $3.3 Million, Compared to $147,000 in 2018 - - More than Doubles Adjusted EBITDA to $6.2 Million, Compared to $2.9 Million in 2018- - Increases Franchise Licenses Sales to 126, Compared to 99 in 2018- -

March 5, 2020 EX-99.2

© 2019 The Joint Corp. All Rights Reserved. 1 Q4 2019 Financial Results As of December 31, 2019 | Reported On March 5, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "for

EXHIBIT 99.2 © 2019 The Joint Corp. All Rights Reserved. 1 Q4 2019 Financial Results As of December 31, 2019 | Reported On March 5, 2020 Safe Harbor Statement © 2020 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements." We have tried to identify these forward - look ing statements by using words such as "may," "might," " will,"

March 5, 2020 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 3, 2020 The Joint Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001-36724 90-0544160 (State or Other Jurisdiction of Incorporation) (Commission File Number)

March 3, 2020 EX-10.2

Pledge and Security Agreement, dated as of February 28, 2020 (the “Pledge and Security Agreement”), among the Company and JPMorgan Chase Bank, N.A., as Administrative Agent

Exhibit 10.2 EXECUTION VERSION PLEDGE AND SECURITY AGREEMENT THIS PLEDGE AND SECURITY AGREEMENT (as it may be amended, restated, supplemented or otherwise modified from time to time, this “Security Agreement”) is entered into as of February 28, 2020 by and among THE JOINT CORP., a Delaware corporation (the “Borrower”), and any additional entities which become parties to this Security Agreement by

March 3, 2020 EX-10.3

Term A Loan Note dated February 28, 2020

Exhibit 10.3 EXECUTION VERSION TERM A LOAN NOTE $5,500,000 Chicago, Illinois February 28, 2020 FOR VALUE RECEIVED, the undersigned THE JOINT CORP., a Delaware corporation (herein, together with its successors and assigns, the “Borrower”), hereby promises to pay to JPMORGAN CHASE BANK, N.A. (the “Lender”) or its registered assignees, in lawful money of the United State of America and in immediately

March 3, 2020 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 28, 2020 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 001-36724 90-0544160 (State or other juris- (Commission file (IRS employer diction of

March 3, 2020 EX-10.4

Revolving Loan Note dated February 28, 2020

Exhibit 10.4 EXECUTION VERSION REVOLVING LOAN NOTE $2,000,000 Chicago, Illinois February 28, 2020 FOR VALUE RECEIVED, the undersigned THE JOINT CORP., a Delaware corporation (herein, together with its successors and assigns, the “Borrower”), hereby promises to pay to JPMORGAN CHASE BANK, N.A. (the “Lender”) or its registered assignees, in lawful money of the United States of America and in immedia

March 3, 2020 EX-10.1

Credit Agreement, dated as of February 28, 2020 (the “Credit Agreement”), among the Company, the Lenders Party Hereto, and JPMorgan Chase Bank, N.A., as Administrative Agent and Sole Bookrunner and Sole Lead Arranger

Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of February 28, 2020 among THE JOINT CORP. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page ARTICLE I. Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. Classification of Loans and Borrowings. 28 SECTION 1.03. Te

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista